MTOR and central nervous system cancer: We previously demonstrated that efficacy of combined MEK and PI3K/mTOR inhibition for the treatment of high-grade gliomas driven by BRAFV600E [27]; our latest results suggest that combined MEK and PI3K/mTOR inhibition is a rational therapy for the treatment of gliomas driven by fusion genes containing the BRAF-KD as well.